Related references
Note: Only part of the references are listed.Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
Luca Malcovati et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
Stuart L. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Iron chelation therapy in MDS: Does it improve survival?
Heather A. Leitch
LEUKEMIA RESEARCH (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Norbert Gattermann et al.
LEUKEMIA RESEARCH (2010)
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
Peter L. Greenberg et al.
LEUKEMIA RESEARCH (2010)
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
V. Santini et al.
LEUKEMIA RESEARCH (2010)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
Jelena M. Kao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Anemia and mortality in heart failure patients - A systematic review and meta-analysis
Hessel F. Groenveld et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
Luca Malcovati
LEUKEMIA RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)